Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Globe Newswire•09/11/2026•16:05 ET
0
Key Highlights
- ➤ATTO-1310 Phase 1b: 82% achieved PP-NRS4 versus 22% placebo at Week 12
- ➤$395.9 million cash, equivalents, and securities supports operations into 2030
- ➤Phase 2 ATTO-1310 trials in CPUO and high-itch AD targeted for 1H 2027
- ➤Q3 net loss $22.3 million versus $13.8 million year over year
- ➤IPO raised approximately $332.4 million in aggregate gross proceeds
Expert Statements
Tao Fu, Founder and Chief Executive Officer of Attovia Therapeutics
“During the third quarter, we continued to execute on our clinical development priorities, positioning Attovia for an exciting and potentially transformative year ahead”
Tao Fu, Founder and Chief Executive Officer of Attovia Therapeutics
“The recently announced 12-week topline results from our ATTO-1310 Phase 1b trial exceeded our expectations, building on the compelling Week 4 findings and providing further evidence supporting our differentiated target product profile: rapid, deep, and durable itch relief, meaningful skin lesion improvements, the potential for quarterly dosing, and a favorable safety profile.”
Tao Fu, Founder and Chief Executive Officer of Attovia Therapeutics
“These results reinforce our confidence in ATTO-1310’s potential to become a next-generation IL-31 therapy for millions of patients suffering from chronic itch conditions.”
Tao Fu, Founder and Chief Executive Officer of Attovia Therapeutics
“We have also made significant progress in preparing for our two Phase 2 ATTUNE trials in CPUO and high-itch AD, both of which remain on track to initiate in the first half of 2027.”
Tao Fu, Founder and Chief Executive Officer of Attovia Therapeutics
“In parallel, we continue to advance ATTO-2306 and ATTO-1091 toward clinical development, positioning Attovia for multiple important milestones in 2027.”
Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD)
Initiation of global Phase 2 trials of ATTO-1310 in patients with chronic pruritus of unknown origin (CPUO) and high-itch AD expected in 1H 2027
Get started
Create a free account to read the full story.